local imaging of the prostate to guide diagnosis and local therapy and whole-body imaging to detect and guide treatment of metastatic disease, transrectal ultrasonography (TRUS), standard TRUS-guided systematic biopsy
Non Muscle Invasive Bladder Cancer (NMIBC), Sequential Gemcitabine and Docetaxel, Bacillus Calmette-Guérin (BCG), Gem/Doce. global BCG supply shortage, radical cystectomy, efficacy of sequential Gem/Doce treatment…
Zach Klaassen and Gautam (Tom) Jayram explore the use of blue light cystoscopy in bladder cancer. Dr. Jayram explains its mechanism, where an optical agent,…
Sam Chang engages with Josh Meeks to discuss nadofaragene firadenovec’s role in treating BCG-unresponsive bladder cancer. They consider the significance of clinical trials and FDA…
Michael Morris highlights notable prostate cancer trials, focusing on AMG 509, a bispecific antibody targeting STEAP1 and CD3. This promising early-phase study, still determining optimal…
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), apalutamide, enzalutamide, Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer,…
Asmaa El-Kenawi discusses her group’s research on therapeutic resistance in cancer, particularly focusing on the role of methionine in driving resistance. Published in “Cancer Research,”…
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer. This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Matthew…
bladder cancer, Circulating Tumor DNA (ctDNA), Residual Disease Detection, imvigor010 study, immunotherapy, adjuvant therapy, urine tumor DNA markers, treatment of invasive bladder cancer.
Tanya Stoyanova discusses research on Trop2’s role in prostate cancer, published in Nature Scientific Reports. Collaborating with Drs. Michael Liss and Jim Brooks, the study…
bladder cancer, metastatic urothelial carcinoma, EV-302 trial, KEYNOTE-A39 study, enfortumab vedotin, pembrolizumab, enfortumab vedotin plus pembrolizumab, CheckMate 901 study, nivolumab plus gemcitabine/cisplatin, nivolumab, gemcitabine, antibody-drug…
